COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Young Adult and Pediatric Bipolar Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00350857
Recruitment Status : Completed
First Posted : July 11, 2006
Last Update Posted : February 20, 2014
Information provided by (Responsible Party):
Validus Pharmaceuticals

Brief Summary:
To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.

Condition or disease Intervention/treatment Phase
Bipolar I Disorder Drug: Extended-Release Carbamazepine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 161 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder.
Study Start Date : July 2006
Actual Primary Completion Date : October 2007
Actual Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Equetro active Drug: Extended-Release Carbamazepine

Primary Outcome Measures :
  1. Safety and tolerability as assessed by the occurrence of treatment emergent adverse events and evaluations of clinical laboratory values, physical examinations, vital signs and ECG data after 6 months of treatment. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Reduction of bipolar symptoms as assessed by the Young Mania Rating Scale (YMRS), Clinical Global Impressions Scale (CGI) and Children's Depression Rating Scale (CDRS-S) after 6 months of treatment. [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Key Inclusion Criteria:

    1. DSM-IV diagnosis of bipolar I disorder, most recent episode manic or mixed.
    2. A lifetime history of bipolar disorder symptoms for at least 2 months.
    3. YMRS score greater than or equal to 16.
    4. CGI-S score greater than or equal to 4.
    5. Male or female outpatient aged between 10-17 years old inclusive at the time of consent.
    6. Functioning at an age-appropriate level intellectually, as deemed by the Investigator.
    7. The subject has no co-morbid illness that could affect efficacy, safety, or tolerability or in any way interfere with the subject's participation in the study.
    8. Must have a satisfactory medical assessment with no clinically significant and relevant abnormalities.

Exclusion Criteria:

  • Key Exclusion Criteria:

    1. Current controlled or uncontrolled, co-morbid psychiatric diagnosis that could interfere with clinical assessments or study conduct.
    2. A history of lack of therapeutic response or hypersensitivity to the study drug.
    3. A greater than or equal to 50% reduction in YMRS between Screening and Baseline.
    4. Acutely at risk for suicidal or violent behavior or a history of suicide attempts requiring medical intervention.
    5. A history of aplastic anemia, agranulocytosis or bone marrow depression.
    6. A history of seizure disorder, other than a single childhood febrile seizure.
    7. A history of severe, unstable asthma.
    8. Current hospitalization for psychiatric symptoms.
    9. History of alcohol or other substance abuse or dependence.
    10. Pregnant or lactating females.
    11. Body weight less than or equal to 25 kg.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00350857

Hide Hide 26 study locations
Layout table for location information
United States, Florida
11 Shire Clinical Research Site
Altamonte Springs, Florida, United States, 32701
17 Segal Institute for Clinical Research
Fort Lauderdale, Florida, United States, 33319
19 Sarkis Clinical Trials
Gainesville, Florida, United States, 32607
23 Shire Clinical Research Site
Jacksonville, Florida, United States, 32256
21 Scientific Clinical Research
North Miami, Florida, United States, 33161
United States, Georgia
14 Northlake Medical Research
Decatur, Georgia, United States, 30333
United States, Idaho
04 Mountain West Clinical Trials
Eagle, Idaho, United States, 83616
United States, Illinois
25 Capstone Clinical Research
Libertyville, Illinois, United States, 60048
United States, Kansas
15 Psychiatric Associates
Overland Park, Kansas, United States, 66211
United States, Kentucky
27 Owensboro Behavioral Care
Owensboro, Kentucky, United States, 42303
United States, Louisiana
05 Brentwood Research Institute
Shreveport, Louisiana, United States, 71101
United States, Maryland
13 Pharmasite Research, Inc
Baltimore, Maryland, United States, 21208
United States, New York
02 Finger Lakes Clinical Research
Rochester, New York, United States, 14618
United States, North Carolina
01 Nccacrf
Chapel Hill, North Carolina, United States, 27514
United States, Ohio
06 University of Cincinnati, College of Medicine
Cincinnati, Ohio, United States, 45267
09 Discovery and Wellness Center for Children
Cleveland, Ohio, United States, 44106
United States, Oklahoma
03 IPS Research
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
26 Suburban Research Associates
Media, Pennsylvania, United States, 19063
United States, Texas
12 Claghorn-Lesem Research Clinic
Bellaire, Texas, United States, 77401
07 Center for Pediatric Psychiatry
Dallas, Texas, United States, 75235
24 Red Oak Psychiatry Associates
Houston, Texas, United States, 77090
10 RID Clinical Research, Inc
Lake Jackson, Texas, United States, 77566
United States, Virginia
08 Dominion Clinical Research
Midlothian, Virginia, United States, 23112
22 Brighton Research Group
Virginia Beach, Virginia, United States, 23452
United States, Wisconsin
20 Shire Clinical Research Site
Milwaukee, Wisconsin, United States, 53201
16 Rogers Center for Research and Training
Milwaukee, Wisconsin, United States, 53227
Sponsors and Collaborators
Validus Pharmaceuticals
Layout table for additonal information
Responsible Party: Validus Pharmaceuticals Identifier: NCT00350857    
Other Study ID Numbers: SPD417-311
First Posted: July 11, 2006    Key Record Dates
Last Update Posted: February 20, 2014
Last Verified: November 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers